1629-P: Association between Dyslipidemia and Myosteatosis Evaluated by Abdominal Computed Tomography

Abstract

Introduction: The association between dyslipidemia and myosteatosis measured using muscular quality map in abdominal computed tomography(CT) was analyzed in a large population. Methods: Abdominal CT of 20,210 subjects were evaluated to measure total abdominal muscle area (TAMA) at L3 level. TAMA was segmented into intramuscular adipose tissue and skeletal muscle area (SMA), which was further classified into normal attenuation muscle area (NAMA: good quality muscle) and low attenuation muscle area (LAMA: poor quality muscle). Myosteatosis indices used were SMA/body mass index(BMI), NAMA/BMI, NAMA/TAMA, and LAMA/BMI. Dyslipidemia was defined as high-density lipoprotein cholesterol(HDL-C) less than 40mg/dL in men and 50mg/dL in women, low-density lipoprotein cholesterol(LDL-C) greater than 160mg/dL, or triglycerides(TG) greater than 150mg/dL. Results: According to multiple logistic regression analyses, the odds ratios (ORs) of dyslipidemia according to HDL and LDL definitions showed a decreasing trend with increasing quartiles for SMA/BMI, NAMA/BMI, and NAMA/TAMA (P for trend < 0.001 for all). The adjusted ORs (95% confidence intervals[CIs]) for dyslipidemia in Q2, Q3, and Q4 for NAMA/TAMA compared with Q1 were 0.87 (0.79-0.96), 0.76 (0.69-0.85) and 0.55 (0.49-0.61) according to the HDL definition and 0.93 (0.83-1.05), 0.95 (0.84-1.07), and 0.69 (0.60-0.79) according to the LDL definition. Conversely, the ORs of dyslipidemia according to HDL and LDL showed an increasing trend according to increasing LAMA/BMI quartiles (P for trend < 0.001 for all). Dyslipidemia according to TG did not show a significant association after adjustment. Conclusion: Dyslipidemia according to HDL-C and LDL-C definitions is associated with myosteatosis, positively with bad quality (unhealthy) muscle and negatively with good quality (healthy) muscle. Muscle quality may be an important risk factor for dyslipidemia and ensuing cardiometabolic diseases. Disclosure H.Kim: None. H.Jung: None. Y.Cho: None. W.Lee: None. C.Jung: None.